Gilead, Glympse partner to assess NASH treatment response in trials
Gilead Sciences announced a strategic collaboration with Glympse Bio for clinical development of nonalcoholic steatohepatitis therapy, according to a press release.
The collaboration includes Glympse Bio’s proprietary synthetic biomarkers, which will be used to identify NASH stage and disease progression and for early detection of treatment response in participants of Gilead’s clinical trials.
“We are excited about the opportunity to partner with Glympse Bio to help inform our NASH development program,” Mani Subramanian, MD, PhD, senior vice president of liver disease therapeutics at Gilead Sciences, said in the release. “By utilizing this innovative technology, we hope to better characterize this complex disease and improve our understanding of how our compounds impact disease progression.”
Glympse Bio’s proprietary technology, Glympse Inside, combines synthetic biomarkers with machine learning approaches to identify the stage and monitor progression in conditions such as cancer, fibrosis, inflammation and infections.
“We are very excited about partnering with Gilead, a leader in drug development, to help drive earlier and more favorable outcomes for patients,” Caroline J. Loew, president and CEO of Glympse Bio, said. “Gilead’s commitment to developing innovative medicines in areas of high unmet medical need aligns with our mission of transforming disease detection and measuring treatment response, all with the goal of helping improve the lives of patients.”
Reference: www.gilead.com; www.glympsebio.com